HUSS; Ralf

Patent Applications and Registrations

Patent applications and USPTO patent grants for HUSS; Ralf.The latest application filed is for "protection of the vascular endothelium from immunologically mediated cytotoxic reactions with human cd34-negative progenitor cells".

Company Profile

3.4.17

HUSS; Ralf - Waakirchen DE
Huss; Ralf - Wakirchen DE
Huss; Ralf - 83666 Waakirchen DE

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Protection Of The Vascular Endothelium From Immunologically Mediated Cytotoxic Reactions With Human Cd34-negative Progenitor Cells App 20200289577 - EISSNER; Gunther ; et al.	2020-09-17
Genetically Modified Mesenchymal Stem Cells Expressing Alpha-1 Antitrypsin (aat) App 20200282078 - GUNTHER; Christine ; et al.	2020-09-10
Genetically Modified Mesenchymal Stem Cells Expressing An Immune Response-stimulating Cytokine To Attract And/or Activate Immune App 20200268802 - Gunther; Christine ; et al.	2020-08-27
Genetically Modified Mesenchymal Stem Cells Expressing Alpha-1 Antitrypsin (aat) App 20180000969 - GUNTHER; Christine ; et al.	2018-01-04
Genetically Modified Mesenchymal Stem Cells Expressing An Immune Response-stimulating Cytokine To Attract And/or Activate Immune Cells App 20170239297 - Gunther; Christine ; et al.	2017-08-24
TISSUE INHIBITOR OF METALLOPROTEINASES (Timp) LINKED TO GLYCOSYLPHOSPHATIDYLINOSITOL (Gpi) - ANCHORS FOR TREATMENT OF CANCER AND SKIN LESIONS App 20160271234 - HUSS; RALF ; et al.	2016-09-22
Cd34 Stem Cell-related Methods And Compositions App 20160136207 - Huss; Ralf ; et al.	2016-05-19
Tissue inhibitor of metalloproteinases (TIMP) linked to glycosylphosphatidylinositol (GPI)-anchors for treatment of cancer and skin lesions Grant 9,255,139 - Huss , et al. February 9, 2	2016-02-09
Protection Of The Vascular Endothelium From Immunologically Mediated Cytotoxic Reactions With Human Cd34-negative Progenitor Cells App 20160008401 - Eissner; Gunther ; et al.	2016-01-14
Cd34 Stem Cell-related Methods And Compositions App 20150238541 - Huss; Ralf ; et al.	2015-08-27
Cd34 Stem Cell-related Methods And Compositions App 20150238526 - Huss; Ralf ; et al.	2015-08-27
Chemokine-Mucin Fusions Linked to Glycosylphosphatidylinositol (GPI)-Anchors in Tissue Regeneration and as Tumour Immune Adjuvants App 20120208769 - Nelson; Peter Jon ; et al.	2012-08-16
CD34 Stem Cell-Related Methods and Compositions App 20110268714 - HUSS; Ralf ; et al.	2011-11-03
CD34 stem cell-related methods and compositions Grant 7,998,472 - Huss , et al. August 16, 2	2011-08-16
Tissue Inhibitor of Metalloproteinases (Timp) Linked to Glycosylphosphatidylinositol (Gpi) - Anchors for Treatment of Cancer and Skin Lesions App 20110105407 - Huss; Ralf ; et al.	2011-05-05
CD34 Stem cell-related methods and compositions App 20090041735 - Huss; Ralf ; et al.	2009-02-12
Genetically modified CD34-negative adherently growing stem cells and their use in gene therapy Grant 6,361,997 - Huss March 26, 2	2002-03-26

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.